In contrast to BAL fluid, intracellular GSH (overall P = 0.035) was lower in SA ( P = 0.010) compared with HC patients
coverage under the Bridge
Understanding your genetic predispositions in peptide pathways may help provide context for why two patients on identical Ozempic doses experience different outcomes
First - paraphrasing Andy Grove - it pays to be paranoid
Manufacturers that offer short lead times allow founders to move from concept to market much faster
reports institutional payments for consultancy fees and/or grants from AstraZeneca, Boehringer Ingelheim, BridgeBio, Ionis, Novartis, Novo Nordisk, Pfizer, Pharmacosmoc, Pharma Nord and Vifor